Matrix metalloproteinase-3 inhibitor retards treadmill running-induced cartilage degradation in rats

Arthritis Research & Therapy

Guo-Xin Ni¹  Li-Qiong Zhan²  Mei-Qin Gao³  Lei Lei²  Yue-Zhu Zhou²  Yan-Xia Pan² 

[1] Department of Orthopeadics and Traumatology, Nanfang Hospital, Southern Medical University, Guangzhou Road 1838, 510515, Guangzhou, China

[2] Department of Rehabilitation Medicine, Fujian Medical University, Fuzhou, Fujian, China

[3] Institute of Cancer, Fujian Medical University, Fuzhou, Fujian, China

关键词: inhibitor;    osteoarthritis;    cartilage;    MMP-3;    running exercise;   

Others  :  1098409
DOI  :  10.1186/ar3521

 received in 2011-07-14, accepted in 2011-11-24,  发布年份 2011

【 摘 要 】

Introduction

The effect of intra-articular injection of matrix metalloproteinase (MMP)-3 inhibitor was investigated in a rat model to understand the role of MMP-3 in cartilage degradation induced by excessive loading from running.

Methods

A total of 24 male Wistar rats were randomly assigned into groups of sedentary control (SED), high-intensity running (HIR), HIR + low dosage of MMP-3 Inhibitor I (HIRI1), and HIR + high dosage of MMP-3 Inhibitor I (HIRI2). Rats in the HIR, HIRI1 and HIRI2 groups were intensively trained for six weeks on the treadmill. Those in HIRI1 and HIRI2 groups were provided bilateral intra-articular injections of 80 μL of 0.2 mM and 2 mM MMP-3 Inhibitor I in knee joints once a week, respectively. Blood samples were collected to measure serum MMP-3 level using ELISA. Femoral condyles were collected to observe cartilage characteristics by histochemistry, and MMP-3 as well as collagen II was measured by immunohistochemistry. In addition, cartilage samples were obtained to assess MMP-3 mRNA expression by RT-PCR.

Results

Histological examination showed osteoarthritic changes in rats after six weeks of high intensity running. In comparison to the SED group, significant decreases in glycosaminoglycans (GAG) and collagen content were found in the HIR group, which corresponded to significant increase in serum MMP-3 level, cartilage MMP-3 activity and gene expression. However, such a degradative process was considerably retarded by intra-articular injection of MMP-3 inhibitor at higher dosage. Statistical differences were found between the HIR and HIRI2 groups with regard to GAG and collagen II content, serum MMP-3 level, cartilage MMP-3 activity and gene expression.

Conclusions

High-intensity running for six weeks may lead to cartilage degradation in a rat model. It was shown that the chrondroprotective effect was offered by the use of intra-articular injection of MMP-3 inhibitor. MMP-3 acts as the key mediator of this catabolic change under such mechanical condition. The results also showed that MMP-3 selective inhibitor may be an effective option for retarding such osteoarthritic changes.

【 授权许可】

   
2011 Ni et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Saxon L, Finch C, Bass S: Sports participation, sports injuries and osteoarthritis: implications for prevention. Sports Med 1999, 28:123-135.
• [2]Chang Q, Huang C, Huang Z: Matrix metalloproteinases and inhibitor in knee synovial fluid as cartilage biomarkers in rabbits: the effect of high-intensity jumping exercise. J Surg Res 2007, 140:149-157.
• [3]Vanwanseele B, Lucchinetti E, Stussi E: The effects of immobilization on the characteristics of articular cartilage: current concepts and future directions. Osteoarthritis Cartilage 2002, 10:408-419.
• [4]Otterness IG, Eskra JD, Bliven ML: Exercise protects against articular cartilage degeneration in the hamster. Arthritis Rheum 1998, 41:2068-2076.
• [5]Kaiki G, Tsuji H, Yonezawa T, Sekido H, Takano T, Yamashita S, Hirano N, Sano A: Osteoarthrosis induced by intra-articular hydrogen peroxide injection and running load. J Orthop Res 1990, 8:731-740.
• [6]Galois L, Etienne S, Grossin L, Watrin-Pinzano A, Cournil-Henrionnet C, Loeuille D, Netter P, Mainard D, Gillet P: Dose-response relationship for exercise on severity of experimental osteoarthritis in rats: a pilot study. Osteoarthritis Cartilage 2004, 12:779-786.
• [7]Pap G, Eberhardt R, Sturmer I, Machner A, Schwarzberg H, Roessner A, Neumann W: Development of osteoarthritis in the knee joints of Wistar rats after strenuous running exercise in a running wheel by intracranial self-stimulation. Pathol Res Pract 1998, 194:41-47.
• [8]Lee YJ, Park JA, Yang SH, Kim KY, Kim BK, Lee EY, Lee EB, Seo JW, Echtermeyer F, Pap T, Song YW: Evaluation of osteoarthritis induced by treadmill-running exercise using the modified Mankin and the new OARSI assessment system. Rheumatol Int 2011, 31:1571-1576.
• [9]Sun HB: Mechanical loading, cartilage degradation, and arthritis. Ann N Y Acad Sci 2010, 1211:37-50.
• [10]Aigner T, McKenna L: Molecular pathology and pathobiology of osteoarthritic cartilage. Cell Mol Life Sci 2002, 59:5-18.
• [11]Cawston TE, Wilson AJ: Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol 2006, 20:983-1002.
• [12]Burrage PS, Mix KS, Brinckerhoff CE: Matrix metalloproteinases: role in arthritis. Front Biosci 2006, 11:529-543.
• [13]Blain EJ, Mason DJ, Duance VC: Effect of mechanical stimulation on MMP expression in chondrocytes. Biorheology 2003, 40:111-117.
• [14]Jin G, Sah RL, Li YS, Lotz MJ, Shyy YJ, Chien S: Biomechanical regulation of matrix metalloproteinase-9 in cultured chondrocytes. J Orthop Res 2000, 18:899-908.
• [15]Trindade MC, Shida DJ, Ikenoue T, Lee MS, Lin EY, Yaszay B, Yerby S, Goodman SB, Schurman DJ, Smith RL: Intermittent hydrostatic pressure inhibits matrix metalloproteinase and proinflammatory mediator release from human osteoarthritic chondrocytes in vitro. Osteoarthritis Cartilage 2004, 12:729-735.
• [16]Leong DJ, Gu X, Lee JY, Li Y, Mahammud R, Majeska RJ, Cardoso L, Sun HB: Matrix metalloproteinase-3 in articular cartilage is upregulated by joint immobilization and suppressed by passive joint motion. Matrix Biol 2010, 29:420-426.
• [17]Aigner T, Zien A, Gehrsitz A, Gebhard PM, McKenna L: Anabolic and catabolic gene expression pattern analysis in normal versus osteoarthritic cartilage using complementary DNA-array technology. Arthritis Rheum 2001, 44:2777-2789.
• [18]Blom AB, van Lent PL, Libregts S, Holthuysen AE, van der Kraan PM, van Rooijen N, van den Berg WB: Crucial role of macrophages in matrix metalloproteinase-mediated cartilage destruction during experimental osteoarthritis: involvement of matrix metalloproteinase 3. Arthritis Rheum 2007, 56:147-157.
• [19]Bedford TG, Tipton CM, Wilson NC, Oppliger RA, Gisolfi CV: Maximum oxygen consumption of rats and its changes with various experimental procedures. J Appl Physiol 1979, 47:1278-1283.
• [20]Buckwalter JA, Martin JA: Osteoarthritis. Adv Drug Deliv Rev 2006, 58:150-167.
• [21]Blain EJ: Mechanical regulation of matrix metalloproteinases. Front Biosci 2007, 12:507-527.
• [22]Lin PM, Chen CTC, Torzilli PA: Increased stromelysin-1 (MMP-3), proteoglycan degradation (3B3-and 7D4) and collagen damage in cyclically load-injured articular cartilage. Osteoarthritis Cartilage 2004, 12:485-496.
• [23]Catterall JB, Stabler TV, Flannery CR, Kraus VB: Changes in serum and synovial fluid biomarkers after acute injury (NCT00332254). Arthritis Res Ther 2010, 12:R229. BioMed Central Full Text
• [24]Manicourt DH, Fujimoto N, Obata K, Thonar EJ: Serum levels of collagenase, stromelysin-1, and TIMP-1: age- and sex-related differences in normal subjects and relationship to the extent of joint involvement and serum levels of antigenic keratin sulfate in patients with osteoarthritis. Arthritis Rheum 1994, 37:1774-1783.
• [25]Sasaki S, Iwata H, Ishiguro N, Obata K, Miura T: Detection of stromelysin in synovial fluid and serum from patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol 1994, 13:228-233.
• [26]Yoshihara Y, Obata K, Fujimoto N, Yamashita K, Hayakawa T, Shinmei M: Increased levels of stromelysin-1 and tissue inhibitor of metalloproteinases-1 in sera from patients with rheumatoid arthritis. Arthritis Rheum 1995, 38:969-975.
• [27]Lohmander LS, Brandt KD, Mazzuca SA, Katz BP, Larsson S, Struglics A, Lane KA: Use of the plasma stromelysin (Matrix Metalloproteinase-3) concentration to predict joint space narrowing in knee osteoarthritis. Arthritis Rheum 2005, 52:3160-3167.
• [28]Poole AR: Biochemical/immunochemical biomarkers of osteoarthritis: utility for prediction of incident or progressive osteoarthritis. Rheum Dis Clin North Am 2003, 29:803-818.
• [29]Weightman B, Freeman MAR, Swann AC: Fatigue of articular cartilage. Nature 1973, 244:303-304.
• [30]Quinn TM, Allen RG, Schalet BJ, Perumbuli P, Hunziker EB: Matrix and cell injury due to sub-impact loading of adult bovine articular cartilage explants: effects of strain rate and peak stress. J Orthop Res 2001, 19:242-249.
• [31]Torzilli PA, Grigiene R, Borrelli J Jr, Helfet D: Effect of impact load on articular cartilage: cell metabolism and viability, and matrix water content. J Biomech Eng 1999, 121:433-441.
• [32]Blanco FJ, Guitian R, Vazquez-Martul E, de Toro FJ, Galdo F: Osteoarthritis chondrocytes die by apoptosis. A possible pathway for osteoarthritis pathology. Arthritis Rheum 1998, 41:284-289.
• [33]Bobacz K, Erlacher L, Smolen J, Soleiman A, Graninger WB: Chondrocyte number and proteoglycan synthesis in the aging and osteoarthritic human articular cartilage. Ann Rheum Dis 2004, 63:1618-1622.
• [34]Kuhn K, D'Lima DD, Hashimoto S, Lotz M: Cell death in osteoarthritis. Osteoarthritis Cartilage 2004, 12:1-16.
• [35]Aranapakam V, Davis JM, Grosu GT, Baker J, Ellingboe J, Zask A: Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis. J Med Chem 2003, 46:2376-2396.
• [36]Sabatini M, Lesur C, Thomas M, Chomel A, Anract P, de Nanteuil G, Pastoureau P: Effect of inhibition of matrix metalloproteinases on cartilage loss in vitro and in a guinea pig model of osteoarthritis. Arthritis Rheum 2005, 52:171-180.
• [37]Brewster M, Lewis EJ, Wilson KL, Greenham AK, Bottomley MK: Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis. Arthritis Rheum 1998, 41:1639-1644.
• [38]Natchus MG, Bookland RG, De B, Almstead NG, Pikul S, Janusz MJ, Heitmeyer SA, Hookfin EB, Hsieh LC, Dowty ME, Dietsch CR, Patel VS, Garver SM, Gu F, Pokross ME, Mieling GE, Baker TR, Foltz DJ, Peng SX, Bornes DM, Strojnowski MJ, Taiwo YO: Development of new hydroxamate matrix metalloproteinase inhibitors derived from functionalized 4-aminoprolines. J Med Chem 2000, 43:4948-4963.
• [39]Clark IM, Parker AE: Metalloproteinases: their role in arthritis and potential as therapeutic targets. Expert Opin Ther Targets 2003, 7:19-34.
• [40]Renkiewicz R, Qiu L, Lesch C, Sun X, Devalaraja R, Cody T: Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum 2003, 48:1742-1749.
• [41]Li NG, Shi ZH, Tang YP, Wang ZJ, Song SL, Qian LH, Qian DW, Duan JA: New hope for the treatment of osteoarthritis through selective inhibition of MMP-13. Curr Med Chem 2011, 18:977-1001.